Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Green synthesis of Simarouba glauca seed-mediated silver nanoparticles: physicochemical characterization and cytotoxic mechanisms in HepG2 hepatocellular carcinoma cells.

Created on 14 Jul 2026

Authors

V Mariya Angel Augasta, Venkatesh Rajendran, B Kowsalya, R T Narendhirakannan, S Kathiravan, Shobana Sampath, Mohammad Z Ahmed, M Dhinakaran, Jayasutha Jayram, Ali Kudamba

Published in

Discover nano. Volume 21. Issue 1. Jul 14, 2026. Epub Jul 14, 2026.

Abstract

This study aims to synthesize Simarouba glauca seed-mediated silver nanoparticles (Sg-AgNPs) through an eco-friendly approach and to evaluate their antioxidant, anti-inflammatory, and anticancer efficacy against HepG2 hepatocellular carcinoma cells. To characterize biosynthesized Sg-AgNPs' optical properties, functional groups, crystallinity, morphology, particle size, and elemental composition, UV-Visible spectroscopy, FT-IR, XRD, SEM, TEM, and EDX were used. Nanoparticles exhibiting a surface plasmon resonance peak at 430 nm and TEM showing 15-60 nm spherical particles. Studies showed considerable antioxidant, anti-inflammatory, and cytotoxic actions against HepG2 cells, with an IC₅₀ value of 42.7 µg/mL. Sg-AgNPs limit cancer cell growth via oxidative stress and apoptosis. These results demonstrate Simarouba glauca-mediated AgNPs as a durable and physiologically beneficial nanoplatform for hepatocellular carcinoma therapy.

PMID:
42446613
Bibliographic data and abstract were imported from PubMed on 14 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement